FLT1
Recombinant Human VEGFR-1 / FLT-1 (Fc Tag)

Catalog No.	CRH395A-Fc	**Quantity:**	20 µg
	CRH395B-Fc		50 µg

Alternate Names: Vascular endothelial growth factor receptor 1, Fms-like tyrosine kinase 1, Tyrosine-protein kinase FRT, Tyrosine-protein kinase receptor FLT, Vascular permeability factor receptor

Description: Vascular endothelial growth factor receptor 1, also known as VEGFR-1, Fms-like tyrosine kinase 1, Tyrosine-protein kinase FRT, Tyrosine-protein kinase receptor FLT, Vascular permeability factor receptor and FLT1, is a single-pass type I membrane protein and secreted protein which belongs to theprotein kinase superfamily, Tyr protein kinase family and CSF-1/PDGF receptor subfamily. VEGFR-1 / FLT1 contains sevenIg-like C2-type (immunoglobulin-like) domains and oneprotein kinase domain. VEGFR-1 / FLT1 is expressed mostly in normal lung, but also in placenta, liver, kidney, heart and brain tissues. It is specifically expressed in most of the vascular endothelial cells, and also expressed in peripheral blood monocytes. VEGFR-1 / FLT1 is not expressed in tumor cell lines. VEGFR-1 / FLT1 is an essential receptor tyrosine kinase that regulates mammalian vascular development and embryogenesis. EGF-induced angiogenesis requires inverse regulation of VEGFR-1 and VEGFR-2 in tumor-associated endothelial cells. VEGFR-1 / FLT1 is a receptor for VEGF, VEGFB and PGF. It has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability.

UniProt ID: P17948

Accession Number: NP_001153503.1

Protein Construction: A DNA sequence encoding the human FLT1 (NP_001153503.1) (Met1-Ile328) was expressed with the Fc region of human IgG1 at the C-terminus.

Source: HEK293 Cells

Molecular Weight: The recombinant human FLT1 consists 543 amino acids and predicts a molecular mass of 61.1 kDa.

Formulation: Lyophilized from sterile PBS, pH 7.4.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.

Purity: > 95 % as determined by SDS-PAGE.

Endotoxin Level: < 1.0 EU per µg protein as determined by the LAL method.

Biological Activity: 1.Measured by its binding ability in a functional ELISA.
2.Immobilized human VEGFR1-Fc at 10µg/mL (100µL/well) can bind biotinylated human VEGF165, the EC50 of biotinylated human VEGF165 is 10-40 ng/mL.

Predicted N-terminal: Ser 27

Cell Sciences®
65 Parker Street
Unit 11
Newburyport, MA 01950

Toll Free: 888-769-1246
Phone: 978-572-1070
Fax: 978-992-0298

E-mail: info@cellsciences.com
Website: www.cellsciences.com

Reconstitution: **Centrifuge vial prior to opening.** Add sterile distilled water to a concentration of 0.1 mg/mL and gently pipette the solution up and down the sides of the vial. **DO NOT VORTEX**. Allow several minutes for complete reconstitution.

Storage & Stability: Stable for up to 1 year from date of receipt at -20°C to -80°C
After reconstitution, store working aliquots at -20°C to -80°C.
Avoid repeated freeze-thaw cycles.

In a functional ELISA, immobilized human VEGFR1-Fc at 10 µg/mL (100 µL/well) binds biotinylated hVEGF165, EC50 of biotinylated hVEGF165 is 10-40 ng/mL.



SDS-PAGE



NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

Cell Sciences ®
65 Parker Street
Unit 11
Newburyport, MA 01950

Toll Free: 888-769-1246
Phone: 978-572-1070
Fax: 978-992-0298

E-mail: info@cellsciences.com
Website: www.cellsciences.com